Published 2 months ago

New malaria vaccine approved by World Health Organization

The World Health Organization (WHO) has recommended the use of a cheap malaria vaccine developed by the University of Oxford, which is the second malaria vaccine to be developed.
The R21 vaccine is 75% effective at preventing malaria in seasonal areas and is easier to manufacture and distribute than the previous vaccine.
The rollout of both the R21 and RTS,S vaccines is expected next year, providing a vital additional tool in the fight against malaria.

Insights by Ground AI

Does this summary seem wrong?

More
Filters

67 Articles

All

Left

Center

Right

Times of India

WHO recommends second malaria vaccine for children

The World Health Organization (WHO) has recommended an additional malaria vaccine for children, which could help save hundreds of thousands of lives. The new R21/Matrix-M vaccine, developed by Oxford University and manufactured by the Serum Institute of India, has already been approved for use in three African countries.

2 months ago·India

Read Full Article

BBC News

Malaria vaccine big advance against major child killer

Deals are in place to make 100 million doses of the vaccine each year to fight the complex disease.

2 months ago·United Kingdom

Read Full Article

News18 India

UN Authorises Second Malaria Vaccine; Experts Warn It's Not Enough to Stop the Disease Spreading

“As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” Tedros said

2 months ago·India

Read Full Article

The Guardian

New malaria vaccine approved by World Health Organization

‘Safe and effective’ R21/Matrix-M vaccine, developed by the University of Oxford, is the first malaria vaccine to reach target of 75% efficacyA highly effective malaria vaccine has been recommended for widespread use by the World Health Organization.The R21/Matrix-M vaccine, developed by the University of Oxford, is only the second malaria vaccine to be recommended by the WHO. It is the first to meet the WHO’s target of 75% efficacy. Continue re…

2 months ago·London, United Kingdom

Read Full Article

The Hindu

Oxford-Serum institute malaria vaccine recommended for use by WHO

WHO recommends R21/Matrix-M malaria vaccine developed by Oxford and Serum Institute of India. Vaccine has met safety, quality and effectiveness standards. Serum Institute has established production capacity for 100 million doses/annum. Vaccine efficacy over 12 months is 75% at sites with high seasonal malaria transmission and 68% at sites with more perennial transmission. Booster dose restores efficacy at seasonal sites with 74% efficacy over 18…

2 months ago·India

Read Full Article